1. Immunology/Inflammation
  2. CD38


CD38 is a glycoprotein found on the surface of many immune cells, including T cells, B cells and natural killer cells. Additionally, CD38 has been shown to be a bifunctional enzyme expressing both ADP-ribosyl cyclase and cADPR hydrolase activities. The role of CD38 in immune cells ranges from modulating cell differentiation to effector functions during inflammation, where CD38 may regulate cell recruitment, cytokine release, and NAD availability. In line with a role in inflammation, CD38 appears to also play a critical role in inflammatory processes during autoimmunity. Because of CD38 expression is highly upregulated on human plasma cells and especially on multiple myeloma cells.Targeting of CD38 is one of the most important and promising treatment avenues to help patients suffering from multiple myeloma.

CD38 Related Products (11):

Cat. No. Product Name Effect Purity
  • HY-129997
    Luteolinidin chloride 98.05%
    Luteolinidin is a natural deoxyanthocyanidin, isolated from Sorghum bicolor [1]. Luteolinidin is a potent CD38 inhibitor which can protect the heart against I/R injury with preservation of eNOS function and prevention of endothelial dysfunction in vivo[2].
  • HY-134358A
    Ara-F-NAD+ sodium Inhibitor
    Ara-F-NAD+ sodium is an arabino analogue of NAD+. Ara-F-NAD+ sodium is a potent, reversible and slow-binding CD38 NADase inhibitor[1][2].
  • HY-144987
    RBN013209 98.87%
    RBN013209 is a potent CD38 inhibitor with an IC50 of 0.01-0.1 μM for human CD38. RBN013209 can be used for the research of of cancer[1].
  • HY-P9915
    Daratumumab 98.70%
    Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition[1][2].
  • HY-123999
    CD38 inhibitor 1
    CD38 inhibitor 1 (compound 78c) is a potent CD38 inhibitor with IC50s of 7.3 nM and 1.9 nM for hCD38 and mouse CD38[1].
  • HY-P99730
    Mezagitamab Inhibitor
    Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP)[1][2][3].
  • HY-P99616
    Felzartamab Inhibitor
    Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research[1][2].
  • HY-P99744
    Modakafusp alfa Inhibitor
    Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules. Modakafusp alfa can be used in the research of multiple myeloma[1].
  • HY-134358
    Ara-F-NAD+ Inhibitor
    Ara-F-NAD+ is an arabino analogue of NAD+. Ara-F-NAD+ is a potent, reversible and slow-binding CD38 NADase inhibitor[1][2].
  • HY-144988
    CD38 inhibitor 2 98.81%
    CD38 inhibitor 2 is a potent CD38 inhibitor (IC50 = 0.01 ~ 0.1 μΜ).
  • HY-150508
    MK-0159 Inhibitor 99.72%
    MK-0159 (compound 37) is an orally active, potent and selective CD38 inhibitor, with IC50 values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart[1].